OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Living with cancer· Appointment prep

Appointment sheet: Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)

One page to bring and write on: your details, the questions for Group 3 and group 4 medulloblastoma (non-WNT/non-SHH) plus your own, the words you may hear, what to bring, the treatments the standard of care names, and room for the answers and agreed next steps. What you type stays in this browser. Print it or save it as a PDF. New to all this? Start with the first 60 days. Orientation, not medical advice.

Tick the questions to print

All of this cancer's questions start ticked. Untick what does not apply; ticks are kept in this browser. .

Your own questions

Shared with the prep pack, so questions you add there appear here too.

Print or save as PDF

Use (or Ctrl+P, Cmd+P on a Mac). To keep a copy, choose Save as PDF as the destination in the print dialog. Only the sheet prints; the controls stay on screen. Your typed notes print where you typed them; empty fields print as ruled lines to write on.

Appointment sheet

Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)

Prepared with OnCo (onco.cc/prep/medulloblastoma-group-3-4/). Orientation, not medical advice; your team knows your case.

My details

Name
Date of appointment
Hospital and clinician
Who is coming with me

What I know, what is unclear, changes to discuss

Saved in this browser
What I know so far
What is unclear to me
Changes since last time

My questions

19 on the sheet
Newly diagnosed
  1. 1.What is my exact diagnosis, stage, and grade, and which tests established them?
  2. 2.Which biomarkers have been tested on my tumour (for example DNA methylation profiling, MYC and MYCN amplification, Isochromosome 17q, Chromosome 11 loss and whole chromosome 17 gain, Metastatic staging by spinal MRI and CSF cytology), and what were the results?
  3. 3.Which subtype is my cancer, and does that change the recommended treatment?
  4. 4.Is germline (inherited) genetic testing recommended for me or my family?
Average risk (aged 3 or over, no metastases, residual under 1.5 square centimetres)
  1. 5.For my situation (average risk (aged 3 or over, no metastases, residual under 1.5 square centimetres)), which of the standard options do you recommend and why?
  2. 6.Am I a candidate for Cisplatin, Vincristine, Cyclophosphamide or related drugs, and what side effects should I expect?
  3. 7.How do the results of COG ACNS0331 apply to someone like me?
High risk (metastatic, residual disease or MYC amplification)
  1. 8.For my situation (high risk (metastatic, residual disease or myc amplification)), which of the standard options do you recommend and why?
  2. 9.Am I a candidate for Carboplatin, Cisplatin, Vincristine or related drugs, and what side effects should I expect?
Infants under three
  1. 10.For my situation (infants under three), which of the standard options do you recommend and why?
  2. 11.Am I a candidate for Methotrexate, Cyclophosphamide, Vincristine or related drugs, and what side effects should I expect?
Relapsed
  1. 12.For my situation (relapsed), which of the standard options do you recommend and why?
  2. 13.Am I a candidate for Temozolomide, Irinotecan (and liposomal irinotecan), Bevacizumab, and what side effects should I expect?
Survivorship
  1. 14.For my situation (survivorship), which of the standard options do you recommend and why?
Any stage
  1. 15.Are there clinical trials I could join, for example of DNA methylation profiling, Proton therapy, Temozolomide, Bevacizumab?
  2. 16.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
  3. 17.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
  4. 18.I read that “MYC and MYCN have no inhibitor, and relapse is almost always fatal”. How does that affect my plan?
  5. 19.I read that “Craniospinal radiotherapy dose cannot be reduced in young children without losing cures”. How does that affect my plan?

The words I may hear

  • Medulloblastoma molecular groups (WNT, SHH, group 3, group 4): Medulloblastoma is four diseases under one microscope: the WNT group is almost always cured, the SHH group depends on age and TP53, and groups 3 and 4 carry most of the deaths, so the group now steers how much radiation and chemotherapy a child receives.
  • Late effects and survivorship toxicity: Health problems appearing months or decades after treatment ends: heart damage, infertility, second cancers, lymphoedema, dry mouth, memory problems, weak bones.

Tests and results to bring

Biomarker results to ask for: DNA methylation profiling (non-WNT/non-SHH subgroups I to VIII), MYC and MYCN amplification, Isochromosome 17q, Chromosome 11 loss and whole chromosome 17 gain (low-risk group 4), Metastatic staging by spinal MRI and CSF cytology (Chang M stage), Residual tumour on postoperative MRI, Large-cell/anaplastic histology.

Scans and tests linked to this cancer: DNA methylation profiling.

Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.

The treatments I may be offered

From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.

Answers and next steps

Saved in this browser
What I was told
Agreed next steps, dates and who to call